One person, one mask, one simple solution for re-use.
The global COVID-19 pandemic has resulted in an acute shortage of Personal Protective Equipment (PPE), specifically N95 or N95 equivalent Respirator masks. Extensive re-use of these single use devices by health care providers is occurring without the ability for decontamination. The CDC recently recognized the decontamination and re-use of N95 or N95 equivalent masks as a crisis capacity strategy.
To help in this fight, Aptar has created ActivShield™ technology, a novel molecular delivery system that provides individualized decontamination of N95 or N95-equivalent masks.
Aptar Requests U.S. FDA Emergency Use Authorization for N95 or N95-equivalent Filtering Facepiece Respirator Decontamination with ActivShieldTM technology
AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 (or N95-equivalent) filtering facepiece respirators. The N95 (or N95-equivalent) masks are desperately needed by Health Care Providers due to the shortage of disposable masks during the COVID-19 pandemic.
Read Press Release | View FAQs | Technology Background